Screener
Apogee Therapeutics, Inc. APGE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashEquivalentsAtCarryingValue.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | MARCH 31,2026 | DECEMBER 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $451,797 | $131,549 |
| Marketable securities | 608,088 | 598,643 |
| Prepaid expenses and other current assets | 13,912 | 11,166 |
| Total current assets | 1,073,797 | 741,358 |
| Long-term marketable securities | 198,354 | 172,730 |
| Property and equipment, net | 5,280 | 5,688 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s cash & equivalents?
- Apogee Therapeutics, Inc. (APGE) reported cash & equivalents of $451.8M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Apogee Therapeutics, Inc.'s cash & equivalents increased by 322.6% year-over-year, from $106.92M to $451.8M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s cash & equivalents?
- Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s cash & equivalents has grown at a -4.7% compound annual growth rate (CAGR), from $151.89M to $131.55M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Apogee Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude